key: cord-0884766-ez8n4l4m
authors: Tworek, Adam; Jaroń, Krzysztof; Uszyńska-Kałuża, Beata; Rydzewski, Andrzej; Gil, Robert; Deptała, Andrzej; Franek, Edward; Wójtowicz, Rafał; Życińska, Katarzyna; Walecka, Irena; Cicha, Małgorzata; Wierzba, Waldemar; Zaczyński, Artur; Król, Zbigniew J.; Rydzewska, Grażyna
title: Convalescent plasma treatment is associated with lower mortality and better outcomes in high risk COVID-19 patients – propensity score matched case-control study
date: 2021-02-16
journal: Int J Infect Dis
DOI: 10.1016/j.ijid.2021.02.054
sha: 0f4414cbf4268e1d9061c35f35b46cadacb6d4da
doc_id: 884766
cord_uid: ez8n4l4m

Objective The aim of the study was to investigate efficacy and safety of convalescent plasma (CP) transfusion in a group of high-risk COVID-19 patients. Methods This prospective study included 204 patients from a single tertiary-care hospital, hospitalized with COVID-19, of whom 102 were treated with CP administration and standard care (PG) and 102 others who received standard care only (CG). The CG was selected from 336 hospitalized patients using the propensity score matching (PSM) technique using age, MEWS score, and comorbidities. The primary outcome was mortality rate; secondary outcomes were the requirement of ventilator, length of ventilator need, length of intensive care unit (ICU) stay, and length of overall hospital confinement. Additionally, parameters predicting death in COVID-19 patients were identified. Results Findings confirmed a significantly lower mortality rate in the PG versus the CG (13.7% vs. 34.3 %, p=0.001) and a significant difference in cumulative incidence of death between the two groups (p <0.001). CP treatment was associated to lower risk of death (OR =0.25 CI 95 [0.06; 0.91], p =0.041). There were no significant differences in ICU stay, ventilator time, and hospitalization time between the two groups. Conclusions A significantly lower mortality rate was observed in the group of patients treated with CP. Age, presence of cardiac insufficiency, active cancer, requirement of ventilator, and length of hospitalization were significantly increasing the risk of death in both groups. Our study shows, that CP brings better outcomes when administrated in the earlier stage of high-risk COVID-19 disease.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a single-strand ribonucleic acid (RNA) virus similar to severe acute respiratory syndrome coronavirus 1 (Cao B. et al., 2020) , tocilizumab (Radbel et al., 2020) , and chloroquine (Cortegiani et al., 2020) . Therefore, the need to investigate additional treatment potentialities remains , Depfenhart et al., 2020 . Convalescent plasma, a strategy of passive immunization, has been used effectively to prevent and treat epidemic infection for more than 100 years (Mair-Jenkins et al., 2015, Marson et al., 2020) . Studies based on previous outbreaks proved good efficacy and no significant side effects (Van den Berg et al., , Wooding et al., 2020 . It has been described that the use of CP in SARS-CoV and avian influenza An H5N1 virus infection decreased viral load in the respiratory tract (Hung et al., 2011 , Kong et al., 2006 . 

The main aim of the study was to investigate the efficacy and safety of treatment with convalescent plasma transfusion in a group of severe COVID-19 patients hospitalized at a tertiary center.

This single-center prospective observational cohort study of 204 patients took place in the J o u r n a l P r e -p r o o f Methods As soon as ten days after a study participant tested negative two times, the participant's plasma was collected. Convalescent plasma to be used for transfusion was tested to confirm compatibility with the AB0 blood type. Each plasma donation produced one to three units (200 milliliters [ml] each). If the titer of IgG antibodies indicated the need for subsequent plasma collection, it occurred after a minimum of 14 days. The TRIMA Accel separator, using automatic apheresis, was used to obtain the plasma. Plasma was treated to inactivate biological pathogens (system Mirasol) (Kwon et al., 2020) .

Level of neutralizing antibodies was measured using Liaison SARS-CoV-2 S1/S2 IgG test 

The primary endpoint for our study was mortality rate and the secondary outcomes were the requirement of ventilator, length of ventilator needs, length of intensive care unit (ICU) stay, overall hospitalization duration, and SARS-CoV-2 elimination time.

Levels of SARS-CoV-2 neutralizing antibodies were assessed in the donor blood.

Additionally, factors associated with mortality in SARS-CoV-2 patients were identified using logistic regression analysis.

Propensity score matching (PSM) analysis was used to balance baseline confounders between plasma and non-plasma groups. Data from previous COVID-19 CP studies led to the assumption of a 28% death rate, indicating a sample size of 95 patients per each of two groups (190 total study participants) would be needed. This number was determined to be large enough to achieve a power of 90% to detect a 65% difference in death rates between the two study groups (28% -65% = 18pp) with a two-sided p-value of 0.05. The control group was chosen from a cohort of 336 COVID-19 patients in one hospital. This method maintains the comparability of the two exposure groups in terms of baseline characteristics. For each patient, we used logistic regression to predict the probability (propensity score) of plasma.

Variables in propensity-score estimation included sex, age, hypertension, arrhythmia, cardiac insufficiency, diabetes, chronic dialysis, diagnosed cancer, and/or recent stroke. The nearestneighbor approach was used to match propensity scores. There were no issues with missing data for variables used in PSM. There was no missing data for sex and age, 1 out of 438 patients had missing data for remaining variables. It was a patient from the plasma group, who was excluded from final analysis before the start of patient matching and data analysis. Since the issue of missing data was marginal, no missing data imputation method was applied.

In order to define the control group, nominal variables were presented as n (% frequency of group), continuous variables as mean (SD -standard deviation), or median (range), depending on normality of data distribution. The Shapiro-Wilk test, based on visual assessment of J o u r n a l P r e -p r o o f histograms, skewness, and kurtosis values, verified data normality. Groups were compared with either the chi-square test or Fisher exact test for nominal variables and with the t-test or Mann-Whitney U test for continuous variables, as appropriate. Additionally, MD (mean or median difference) with 95% confidence interval was calculated for continuous variables.

Relative risk (RR) with 95% confidence interval was calculated for nominal variables.

Survival curves were prepared using the Kaplan-Meier approach and comparison of survival between groups with and without plasma treatment was made using the log-rank test.

Additional analysis using logistic regression was conducted in order to identify parameters impacting death in COVID-19 patients. Initially, univariate models were calculated using all 

There were no significant differences in ICU stay, SARS-CoV-2 elimination time, and ventilator treatment time for both groups. J o u r n a l P r e -p r o o f Parameters predicting death in SARS-CoV-2 patients were identified using logistic regression analysis ( As shown in Figure 2 , the sooner plasma is administrated, the lower the cumulative incidence of death is. At five days, cumulative incidence of death was 12.2%, CI 95 (4.2%; 19.6%); at ten days 21.5%, CI 95 (5.9%; 44.5%). During the study in total, the cumulative incidence of death was found to be 47.7%, CI 95 (0.0%; 77.0%). Figure 2 includes only patients from the plasma group. Its objective was to present survival depending on timing of the 1 st administration of plasma. 

This study compares mortality and other endpoints between patients treated with convalescent plasma (PG) and a propensity-score matched control group (CG) of patients hospitalized in the same medical facility. and demonstrates a significantly lower mortality rate in the PG (13.7% vs. 34.3% in CG, p = 0.001). Recent randomized PlasmAr study (Simonovich et al., 2020) suggest no significant differences in mortality rate between patients treated with convalescent plasma and those who received placebo, however baseline mortality in the untreated group in this study was 11.43% in comparison to 34.3 % in similar group in our hospital.

High mortality rate in our study is probably dependent on high number of comorbidities among our patients in contrary to PlasmAr study (35. 2 % of patients with no coexisting conditions in PlasmAr placebo group vs. 1.96 % in our study). In the tertiary center in which the study was performed, patients at highest risk of complications were treated also during pandemic.

Our result can suggest a benefits of convalescent plasma treatment in high risk COVID-19 patients.

A recently published study from Mayo Clinic showed that early administration of high-titer CP to infected adults reduced the mortality rate and progression of COVID-19. Similar to our study, the benefits of CP treatment were associated with early administration (up to 72 hours from the onset of symptoms) (Ma et al., 2021) .

The authors of the PLACID trial (Agarwal et al., 2020) did not prove reduction in mortality or progression to severe COVID-19 in patients treated with convalescent plasma; however, most of the patients in this study experienced only mild or moderate symptoms (94.2% of all participants). In contrast, CP proved beneficial in a group of patients with severe or lifethreatening disease in Mount Sinai Hospital, New York City ; these patients experienced a significant reduction of oxygen requirement ratio and significantly lower mortality rate. It is worthwhile to mention that the sooner the plasma was administrated, the lower the cumulative incidence of death was observed in our study. On day 5, for example, the cumulative incidence of death was 12.2% but, on day 10, the rate had escalated to 21.5%.

Hegerova et al. report a study of 20 patients treated by CP with severe or critical coronavirus disease that showed best results when transfusion was undertaken within the first seven days of hospitalization (Hegerova et al., 2020) . Similar to our study, that study suggests high-risk patients with comorbidities and severe COVID-19 symptoms receive greater benefit from CP when it is administered in the early stage of hospitalization. We have shown that mortality rate increases proportionally to hospitalization length, which further strengthens the argument for early treatment.

A trial of CP conducted in Wuhan, China (Li et al., 2020) , showed no statistical significance of mortality rate (p = 0.3), however, interpretation of this finding is limited by early termination of the trial. It is worthwhile to mention that some studies of SARS-CoV-2's viral kinetics revealed that naturally reducing viral-antibody titers are seen seven to ten days after onset of symptoms in most patients , Zou et al., 2020 . Nagoba 

This trial took place during the early days of the COVID-19 pandemic, when there were no effective treatment options yet available. Now, enough time has elapsed that multiple studies on potential treatment options are in publication. Some studies involved comparing various potential treatments against each other, such as comparing CP outcomes to those of dexamethasone. In the Roback study, some patients received more than one therapeutic agent, such as giving one patient both antiviral medications and steroids (Roback et al., 2020) . This approach makes it difficult to disentangle the specific clinical responses derived when multiple elements are compared in a study or to single out the beneficial properties of an individual treatment plan.

This study found CP administration to be safe; only one study participant experienced a side effect (mild and temporary skin rash). This finding is in keeping with a study done in the US that produced similar results (Joyner et al., 2020) . Other adverse reactions reported in various studies include immunological reactions or increased risk of infection at the transfusion site; these reactions are typical responses to transfusion of blood products, including plasma. As at the tertiary hospital, baseline mortality in patients during standard treatment was high, a finding that may be similar in other COVID-19 studies.

The basic limitation of this study was lack of randomization, which was replaced by PSM analysis. The decision not to randomize in our study was based on ethical considerations at the beginning of the pandemic, however, the results of this analysis were based on population groups of sufficient size and advanced statistics, as described in methodology.

In summary, convalescent plasma transfusion seems to be safe and effective therapy for SARS-CoV-2 infection in the group of high-risk patients. Moreover, the results of our study may suggest that early administration may be crucial for optimal outcome. This study demonstrated that age, presence of cardiac insufficiency, active cancer, requirement of J o u r n a l P r e -p r o o f 23 ventilator, and/or and length of hospitalization were significantly increasing the risk of death in studied group. Randomized prospective trials in the subgroup of high-risk patient are still needed.

The Authors declares that there is no conflict of interest.

The study was supported by The National Centre for Research and Development in Poland.

Approved (agreement number 40/2020 of 03/04/2020)

Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study

Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicenter randomized controlled trial (PLACID Trial)

Statistical primer: propensity score matching and its alternatives

Clinical and Analytical Performance of an Automated Serological Test That Identifies S1/S2-Neutralizing IgG in COVID-19 Patients Semiquantitatively

A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

SARS-CoV-2 neutralizing antibody levels are correlated with severity of COVID-19 pneumonia

Use of convalescent plasma therapy in SARS patients in Hong Kong

A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19

Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy?

Use of convalescent plasma in hospitalized patients with COVID-19: Case series

Applied Logistic Regression

Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection

Early safety indicators of COVID-19 convalescent plasma in 5000 patients

Successful treatment of avian influenza with convalescent plasma

Pathogen Inactivation Efficacy of Mirasol PRT System and Intercept Blood System for Non-Leucoreduced Platelet-Rich Plasma-Derived Platelets Suspended in Plasma

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial

Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma. Seminars in Thrombosis and Hemostasis

Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study

Viral dynamics in mild and severe cases of COVID-19

The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis

The Role of Disease Severity and Demographics in the Clinical Course of COVID-19

Patients Treated with Convalescent Plasma. medRxiv : the preprint

The true historical origin of convalescent plasma therapy

Positive aspects, negative aspects and limitations of plasma therapy with special reference to COVID-19

Use of Tocilizumab for COVID-19-Induced Cytokine Release Syndrome: A Cautionary Case Report

Convalescent Plasma Transfusion for the Treatment of COVID-19: Systematic Review

Convalescent Plasma to Treat COVID-19: Possibilities and Challenges

Convergent antibody responses to SARS-CoV-2 in convalescent individuals

Convalescent plasma in Covid-19: Possible mechanisms of action

Convalescent Plasma for COVID-19 Close Contacts

Evaluation of a Modified Early Warning Score (MEWS) Adjusted for COVID-19 Patients (CEWS) to Identify Risk of ICU Admission or Death. medRxiv, Web

Diagnostic Accuracy of Six Commercial SARS-CoV-2 IgG/Total Antibody Assays and Identification of SARS-CoV-2 Neutralizing Antibodies in Convalescent Sera

Therapeutic management of patients with COVID-19: a systematic review

COVID-19: Convalescent plasma as a potential therapy

Aerosol and Surface Stability of SARS-CoV-2 as Compared

A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia 2020

Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks

Treatment with convalescent plasma for COVID-19 patients in Wuhan

SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients

Potential interventions for novel coronavirus in China: A systematic review